share_log

Evogene Q2 Revenue Grows 131%, Here Is What You Need To Know

Evogene Q2 Revenue Grows 131%, Here Is What You Need To Know

Evogene第二季度收入增長131%,以下是您需要知道的
Benzinga Real-time News ·  2022/08/31 11:32
Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales of Lavie Bio's Thrivus product (previously branded as Result) and sales of Canonic products in the Israeli market.
Evogene Ltd.納斯達克股票代碼:EVGN)2022年第二季度收入為312,000美元,與去年同期的135,000美元相比增長了131%。收入主要來自於最初的銷售Lavie Bio's 特里弗斯產品(以前的品牌為結果)和銷售正典以色列市場上的產品。
Q2 2022 Financial Highlights
2022年第二季度財務亮點
Net loss was $9.8 million in comparison to a net loss of $6.9 million in the same period in the previous year. R&D expenses for the quarter, which are reported net of non-refundable grants received, were $5.4 million, in comparison to $5.0 million in the same period the previous year. The increase...
NET的損失為980萬美元相比之下,去年同期淨虧損690萬美元。 研發費用在本季度,報告的淨額是收...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論